J Allergy Clin Immunol

AAAAI 2026: Dupilumab bests omalizumab in patients with nasal polyps and asthma

March 3, 2026

In the Phase 4 EVEREST trial (NCT04998604), dupilumab (DPL) with medium‑dose inhaled corticosteroid (DPL+mICS) resulted in stronger clinical gains than omalizumab (OMA) with high‑dose ICS (OMA+hICS) in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and uncontrolled asthma. Baseline nasal polyp score (NPS), pre-bronchodilator forced expiratory volume in 1 second (FEV₁), and 7-item Asthma Control Questionnaire (ACQ‑7) were comparable across groups. By Week 24, DPL+mICS achieved larger improvements in NPS (−2.63 vs. −0.46), FEV₁ (+0.32 L vs. +0.10 L), and ACQ‑7 (−2.03 vs. −1.51), highlighting consistent benefit across upper and lower airway endpoints. These results were presented at the AAAAI 2026 Annual Meeting.

Clinical takeaway: For patients with CRSwNP and uncontrolled asthma, DPL+mICS may provide greater symptom and lung function improvement than omalizumab, even with hICS.

Source:

Wagenmann, Martin et al. (2026, February). J Allergy Clin Immunol. Dupilumab With Medium-Dose Inhaled Corticosteroids Versus Omalizumab With High-Dose Inhaled Corticosteroids Improves Clinical Outcomes In Patients With Coexisting Chronic Rhinosinusitis With Nasal Polyps And Uncontrolled Asthma. https://www.jacionline.org/article/S0091-6749(25)02092-5/fulltext